Researchers report that patients taking GLP-1 receptor agonists can show atypical FDG uptake patterns that may be mistaken for disease
Absorption is slower, and the compound sits in tissue longer, extending the inflammatory window
Caution: Foods, drugs, devices and cosmetic act prohibit dispensing without prescription of a duly licensed veterinarian
Due to a lack of clinical trials, there is a shortage of data on the safety of BPC-157 for use in humans
Our poster highlights preclinical results for our monthly quintuple receptor (GLP-1, GIP, GCG, AMY, and CALC) agonist program, demonstrating extended PK/PD, superior effects on food intake and weight loss compared to retatrutide in DIO rats, with a profile designed to enable both best-in-class efficacy and improved tolerability
Biochem Pharmacol (1998) 55:8116